In pancreatic cancer cells, AGR2 up-regulates the downstream effectors (e.g. cathepsin B and D) without changing their mRNA levels supporting that AGR2 could exert its effects on client proteins post-transcriptionally (Dumartin et al. 2011). This evidence concerns the gene AGR2 and familial pancreatic carcinoma.